Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer

Oncology

Volumn 58, Issue 1, 2000, Pages 31-37

  Sugiyama, Toru ^a,n   Yakushiji, Michiaki ^a   Noda, Kiichiro ^b   Ikeda, Masanori ^b   Kudoh, Ryouichi ^c   Yajima, Akira ^d   Tomoda, Yutaka ^e   Terashima, Yoshiteru ^f   Takeuchi, Shoshichi ^g   Hiura, Masamichi ^h   Saji, Fumitaka ⁱ   Takahashi, Takeshi ^j   Umesaki, Naohiko ^k   Sato, Shinji ^d   Hatae, Masanori ^l   Ohashi, Yasuo ^m  

^a KURUME UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e NAGOYA UNIVERSITY   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Kitatama Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^j Niigata Cancer Center   (Japan)

^k Osaka Prefecture University   (Japan)

^l Kagoshima City Hospital   (Japan)

^m UNIVERSITY OF TOKYO   (Japan)

ⁿ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Cervical cancer; Chemotherapy; Cisplatin; CPT 11; Irinotecan; Topoisomerase I inhibitor

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; IRINOTECAN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOXICITY; ENTEROPATHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IMAGING; INFECTION; LEUKOPENIA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

EID: 0033986530     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012076     Document Type: Article

References (42)

1. Parkin DM, Laara E, Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-197.
2. Nitta K, Yokokura T, Sawada S, Kunimoto T, Tanaka T, Uchara N, Baba H, Takeuchi M, Miyasaka S, Mudai H: Antitumor activity of novel derivatives of camptothecin (in Japanese). Gan To Kagaku Ryoho 1987;14:850-857.
3. Champoux J: Evidence for an intermediate with a singlestrand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA 1976;73:3488-3491.
4. Liu LF, D'Arpa P: Topoisomerase-targeting antitumor drugs: Mechanisms of cytotoxicity and resistance; in DeVita V, Hellman S, Rosenberg S (eds): Important Advances in Oncology. Philadelphia, Lippincott. 1992, pp 79-89.
5. Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M: DNA topoisomerase-I mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989;49: 4385-4389.
6. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifiji N, Kudoh S, NegoroS, Nishioka M, Takada M: A new derivative of camptothecin, for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10: 1225-1229.
7. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992;10:16-20.
8. Shimada Y, Yoshino M, Wakui A, Nakano I, Futatsuki K, Sakata Y, Kambe M, Taguchi T: CPT-11 Gastrointestinal Cancer Study Group. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 1993;11:909-913.
9. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997;15:921-927.
10. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T, Tanizawa O, Sugawa T, Umesaki N, Sekiba T, Aono T, Nakano H, Noda K, Shiota M, Yakushiji M, Sugiyama T, Hashimoto M, Yamaji A, Takamizawa H. Sonoda T, Takeda Y, Tomoda Y, Ohta M, Ozaki M, Hirabayashi K, Hiura M, Hatac M, Nishigaki K, Taguchi T: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer (in Japanese). Gan To Kagaku Ryoho 1991;18:1681-1689.
11. Sugiyama T, Takcuchi S, Noda K, Yakushiji M: Phase I study of irinotecan (CPT-11) in combination with cisplatin in cervical cancer. Proc Am Soc Clin Oncol 1995;13:A1546.
12. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Freedman RS, Edwards CL, Hord M, Sieger M, Kaplan AL, Kicback D, Fishman A, Kavanagh JJ: Phase 11 study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15: 625-631.
13. Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ, Potkul RK: A phase II study of irinotecan (CPT-11) on patients with advanced squamous cell carcinoma of the cervix. Cancer 1998;82:328-333.
14. Bonomi P, Blessing JA, Stchman FB: Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 1985;3:1079-1085.
15. Lahousen M, Pickel H, Tamussmo K: Chemotherapy tor advanced and/or recurrent cervical cancer. Arch Gynecol 1987;240:247-252.
16. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y: Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 1992;50:604-610.
17. Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N: Synergistic enhancement of cisplatin cytotoxicity by SN-38. an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 1994;85:966-971.
18. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y: Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 1995;62: 70-75.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5: 649-655.
20. WHO Handbook for Reporting Results of Cancer Treatment: WHO Offset Publ No 48. Geneva. Switzerland. World Health Organization, 1979.
21. Simon R: Confidence intervals for reporting results of clinical trials. Ann Intern Mod 1986; 105:429-435.
22. Creemer GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996;14:3056-3061.
23. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarhara P, Onetto N, Winograd B, Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer High-dose venus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654-2666.
24. Kaye SB, Piccart M, Aapro M, Kavanagh J: Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials. Eur J Cancer 1995;31A:S14-S17.
25. Lacava JA, Leone BA, Machiavelli M, Romero AO, Perez, JE, Elem YL, Ferreyra R, Focaccia G, Suttora G, Salvadori MA, Cuevas MA, Acuna LR, Acuna JR, Langhi M, Amato S, Castaldi J, Arroyo A, Vallejo CT: Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 1997;15:604-609.
26. Thigpen JT, Vance R, Puneky L, Khansur T: Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 1995;22:16-24.
27. Rose PG, Piver MS, Malfetano JH, Baker TR, Hempling RE, Recio FO: A phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma. Cancer 1993;71:2245-2249.
28. Omura GA, Blessing JA, Vaccarello L. Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 1997;15:165-171.
29. Macia M, Novo A, Gonzales M, Huidobro C, Yustc J, Diah T: Neoadjuvant and salvage chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5-FU) in cervical carcinoma. Eur J Gynaecol Oncol 1993;14:192-196.
30. Kaern J, Trope C, Sundfoer K, Kristensen B: Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: A phase II study with long-term follow-up. Gynecol Oncol 1996;60:387-392.
31. Al-Salch E, Hoskins PJ, Pike JA, Swenerton KD: Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical cancer. Gynecol Oncol 1997;64:468-472.
32. Buxton EJ, Meanwcel CA, Hilton C, Mould JJ, Spooner D, Chetiyawardana A, Latief T, Paterson M, Redman CW, Luesley DM, Blackledge CR: Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989;81:359-361.
33. Hempling RE, Eltabhakh GH, Piver MS, Recio FO, O'Neill CP: The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide docs not improve survival in advanced or recurrent cervical carcinoma. Am J Clin Oncol 1997;20:315-318.
34. Fanning J, Ladd C, Hilgers RD: Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecol Oncol 1995;56:235-238.
35. Smith HO, Stringer A, Kavanagh JJ, Gershenson DM, Edwards CL, Wharton JT: Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomyein-C, bleomycin, and cisplatin chemotherapy. Gynecol Oncol 1993;48:11-15.
36. Lahousen M, Pickel H, Tamussino K: Chemotherapy for advanced and/or recurrent cervical cancer. Arch Gynecol 1987;240:247-252.
37. Sundfor K, Trope CG, Mogherg T, Onsrud M, Koern J, Simonsen E, Bertelsen K, Westberg R: Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma: A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer 1996;7: 2371-2378.
38. Scambia G, Benedetti-Panici P, Foti E, Ferrandina G, Leone FP, Marciano M, Mancuso S: Multiple tumour marker assays in advanced cervical cancer: Relationship to chemotherapy response and clinical outcome. Eur J Cancer 1996;32A:259-263.
39. Tattersall MHN, Lorvidhaya V, Vootiprux V: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. J Clin Oncol 1995;13:444-451.
40. Benedetti-Panici P, Greggi S, Scambia G, Ragusa G, Baiocchi G, Battaglia F, Coronetta F, Mancuso S: High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: A preliminary report. Gynecol Oncol 1991;41: 212-216.
41. Masuda N, Fukuoka N, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takefuji N, Nakagawa K, Kishimoto S: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992;10:1775-1780.
42. Kudoh S, Fijiwara Y, Takada Y, Tamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 1998;16: 1068-1074.